Arax Advisory Partners’s Spyre Therapeutics SYRE Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$16.3K Buy
183
+14
+8% +$1.35K ﹤0.01% 4147
2026
Q2
$15K Buy
169
+151
+839% +$11K ﹤0.01% 4134
2026
Q1
$908 Buy
+18
New +$679 ﹤0.01% 3323
2025
Q4
– Sell
-121
Closed -$2.03K – 4515
2025
Q3
$2.03K Buy
+121
New +$1.97K ﹤0.01% 3114

Other funds holding SYRE

Arax Advisory Partners's SYRE Position: Q3 2026 in Review

Arax Advisory Partners increased its Spyre Therapeutics (SYRE) stake by 8.3% in Q3 2026, buying an estimated $1.35K and bringing the position to 183 shares worth $16.3K. The position accounts for ﹤0.01% of the portfolio, ranked #4147.

Arax Advisory Partners first reported a position in SYRE in Q3 2025 and has held it in 4 quarters since. 193 funds tracked by Wall St. Rank hold SYRE as of Q3 2026.

  • Arax Advisory Partners held 183 shares of Spyre Therapeutics worth $16.3K as of Q3 2026.
  • Arax Advisory Partners bought 14 Spyre Therapeutics shares in Q3 2026, an estimated $1.35K.
  • Spyre Therapeutics made up ﹤0.01% of Arax Advisory Partners's portfolio in Q3 2026, its #4147 holding.
  • Arax Advisory Partners first reported a position in Spyre Therapeutics in Q3 2025 and has held it in 4 quarters since.
  • 193 funds tracked by Wall St. Rank held Spyre Therapeutics as of Q3 2026.

Based on Arax Advisory Partners's 13F filing for Q3 2026, filed 12 Nov 2026.